Importantly, the combination of RP-192 and anti-PD-L1 therapies allowed to overcome ICB resistance in a pancreatic cancer model not known to respond to single agent of anti-PD-1/PD-L1 therapy (75). Here, PDCD1 is linked to familial pancreatic carcinoma.